Phoenix Molecular Designs Doses First Patient with PMD-026 in Dauntless-1 Trial
Phoenix Molecular Designs (PhoenixMD) has initiated Phase 2 clinical trials (Dauntless-1) for PMD-026, a first-in-class pan-RSK inhibitor, in combination...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Phoenix Molecular Designs (PhoenixMD) has initiated Phase 2 clinical trials (Dauntless-1) for PMD-026, a first-in-class pan-RSK inhibitor, in combination...
Saudi Arabia is rapidly becoming a hub for clinical trials in the Middle East, with over 400 active studies...
Neurona Therapeutics, a clinical-stage biotherapeutics company, is initiating its Phase 3 EPIC clinical trial for NRTX-1001, a regenerative cell...
Shattuck Labs announced positive preclinical data from a toxicology study of SL-325, a high-affinity DR3 blocking antibody being developed...
SELLAS Life Sciences announced positive Phase 2a trial data for SLS009 (tambiciclib), a CDK9 inhibitor, combined with Brukinsa (zanubrutinib)...
PolarityBio’s SkinTE received Breakthrough Therapy Designation from the FDA for treating Wagner Grade 1 Diabetic Foot Ulcers (DFUs). This...
Nuwellis, Inc. announced updated findings from the AVOID-HF study, published in the Journal of the American College of Cardiology:...
In this interview, we engage with Dalton Signor, CEO at Miist Therapeutics, to explore their innovative inhaled therapies for...
Vaxxas, a clinical-stage biotech company, has completed enrollment for its Phase I clinical trial of an avian influenza A...
Professor Kim Jae-ho presented positive findings from an exploratory clinical trial using Deepson Bio’s NEUCLARE therapeutic ultrasound device to...